Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Drug Resistance

  Free Subscription


Articles published in J Infect Dis

Retrieve available abstracts of 83 articles:
HTML format
Text format



Single Articles


    October 2019
  1. WEISS E, Schlatterer K, Beck C, Peschel A, et al
    Formyl-peptide receptor activation enhances phagocytosis of community-acquired methicillin-resistant Staphylococcus aureus.
    J Infect Dis. 2019 Oct 1. pii: 5580022. doi: 10.1093.
    PubMed     Text format     Abstract available


    May 2019
  2. BARTSCH SM, Wong KF, Stokes-Cawley OJ, McKinnell JA, et al
    Knowing More of the Iceberg: How Detecting a Greater Proportion of Carbapenem-Resistant Enterobacteriaceae (CRE) Carriers Impacts Transmission.
    J Infect Dis. 2019 May 31. pii: 5509628. doi: 10.1093.
    PubMed     Text format     Abstract available


  3. DUTCHER L, Lautenbach E
    A deeper dive: Implications of identifying more of the Carbapenem-resistant Enterobacteriaceae Iceberg.
    J Infect Dis. 2019 May 31. pii: 5509630. doi: 10.1093.
    PubMed     Text format    


    April 2019
  4. OLESEN SW, Grad YH
    Deciphering the impact of bystander selection for antibiotic resistance in Neisseria gonorrhoeae.
    J Infect Dis. 2019 Apr 8. pii: 5430789. doi: 10.1093.
    PubMed     Text format    


    March 2019
  5. ULLOA ER, Dillon N, Tsunemoto H, Pogliano J, et al
    Avibactam Sensitizes Carbapenem-Resistant NDM-1-Producing Klebsiella pneumoniae to Innate Immune Clearance.
    J Infect Dis. 2019 Mar 29. pii: 5421810. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2019
  6. WANG Y, Ferrer-Espada R, Baglo Y, Goh XS, et al
    Photo-inactivation of Neisseria gonorrhoeae: A paradigm changing approach for combating antibiotic-resistant gonococcal infection.
    J Infect Dis. 2019 Jan 9. pii: 5283517. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2018
  7. SUTHAR AB, Coggin W, Raizes E
    Antimicrobial Resistance and Substandard and Falsified Medicines: The Case of HIV/AIDS.
    J Infect Dis. 2018 Oct 11. pii: 5126519. doi: 10.1093.
    PubMed     Text format    


    July 2018
  8. ZHANG WW, Cheung PK, Oliviera N, Robbins MA, et al
    Accumulation of multiple mutations in vivo confers cross-resistance to new and existing integrase inhibitors.
    J Infect Dis. 2018 Jul 16. pii: 5054084. doi: 10.1093.
    PubMed     Text format     Abstract available


    June 2018
  9. BORGIA SM, Hedskog C, Parhy B, Hyland RH, et al
    Identification of a Novel Hepatitis C Virus Genotype from Punjab, India - Expanding Classification of Hepatitis C Virus into 8 Genotypes.
    J Infect Dis. 2018 Jun 30. pii: 5047409. doi: 10.1093.
    PubMed     Text format     Abstract available


  10. LI L, Abdelhady W, Donegan NP, Seidl K, et al
    Role of Purine Biosynthesis in Persistent Methicillin-Resistant Staphylococcus aureus (MRSA) Infection.
    J Infect Dis. 2018 Jun 2. pii: 5032510. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2018
  11. PHAM HT, Labrie L, Wijting IEA, Hassounah S, et al
    The S230R Integrase Substitution Associated with Viral Rebound during DTG Monotherapy Confers Low Levels INSTI Drug Resistance.
    J Infect Dis. 2018 Mar 29. pii: 4956223. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. WIJTING IEA, Lungu C, Rijnders BJA, van der Ende ME, et al
    HIV-1 resistance dynamics in patients failing dolutegravir maintenance monotherapy.
    J Infect Dis. 2018 Mar 29. pii: 4956224. doi: 10.1093.
    PubMed     Text format     Abstract available


    January 2018
  13. LAMOTH F, Kontoyiannis DP
    The Candida auris Alert: Facts and Perspectives.
    J Infect Dis. 2018;217:516-520.
    PubMed     Text format    


  14. PIRES S, Jacquet R, Parker D
    Inducible Costimulator Contributes to Methicillin-Resistant Staphylococcus aureus Pneumonia.
    J Infect Dis. 2018 Jan 25. pii: 4825828. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. BOUCHER HW, Ambrose PG, Chambers HF, Ebright RH, et al
    Reply to Paul and Leibovici.
    J Infect Dis. 2018;217:509-510.
    PubMed     Text format    


  16. PAUL M, Leibovici L
    Drug Development for Multidrug-Resistant Bacteria: Why Compromise?
    J Infect Dis. 2018;217:508-509.
    PubMed     Text format    


  17. CHEUNG GYC, Fisher EL, McCausland JW, Choi J, et al
    Antimicrobial peptide resistance mechanism contributes to Staphylococcus aureus infection.
    J Infect Dis. 2018 Jan 17. pii: 4812604. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. GENDRIN C, Merillat S, Vornhagen J, Coleman M, et al
    Diminished capsule exacerbates virulence, blood brain barrier penetration, intracellular persistence and antibiotic evasion of hyperhemolytic Group B Streptococcus.
    J Infect Dis. 2018 Jan 2. pii: 4782479. doi: 10.1093.
    PubMed     Text format     Abstract available


    December 2017
  19. STELLA-ASCARIZ N, Arribas JR, Paredes R, Li JZ, et al
    The Role of HIV-1 Drug-Resistant Minority Variants in Treatment Failure.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  20. WALLIS CL, Godfrey C, Fitzgibbon JE, Mellors JW, et al
    Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Countries.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  21. RAIZES E, Hader S, Birx D
    Expansion of Viral Load Testing and the Potential Impact on HIV Drug Resistance.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


    November 2017
  22. ANDREI G, Gillemot S, Topalis D, Snoeck R, et al
    The anti-HIV drug tenofovir, a reverse transcriptase inhibitor, also targets the herpes simplex virus (HSV) DNA polymerase.
    J Infect Dis. 2017 Nov 23. pii: 4653578. doi: 10.1093.
    PubMed     Text format     Abstract available


  23. NAIDOO P, Theron G, Rangaka MX, Chihota VN, et al
    The South African Tuberculosis Care Cascade: Estimated Losses and Methodological Challenges.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  24. BLOOMFIELD SJ, Midwinter AC, Biggs PJ, French NP, et al
    Long-term colonisation by Campylobacter jejuni within a human host: evolution, antimicrobial resistance and adaptation.
    J Infect Dis. 2017 Nov 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2017
  25. SIBERRY GK, Amzel A, Ramos A, Rivadeneira ED, et al
    Impact of Human Immunodeficiency Virus Drug Resistance on Treatment of Human Immunodeficiency Virus Infection in Children in Low- and Middle-Income Countries.
    J Infect Dis. 2017 Oct 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. BERTAGNOLIO S, Beanland RL, Jordan MR, Doherty M, et al
    The World Health Organization's Response to Emerging Human Immunodeficiency Virus Drug Resistance and a Call for Global Action.
    J Infect Dis. 2017 Oct 13. doi: 10.1093.
    PubMed     Text format     Abstract available


  27. DUARTE HA, Panpradist N, Beck IA, Lutz B, et al
    Current Status of Point-of-Care Testing for Human Immunodeficiency Virus Drug Resistance.
    J Infect Dis. 2017 Oct 13. doi: 10.1093.
    PubMed     Text format     Abstract available


  28. SILVERMAN RA, Beck IA, Kiptinness C, Levine M, et al
    Prevalence of Pre-antiretroviral Treatment Drug Resistance by Gender, Age, and Other Factors in HIV-infected Individuals Initiating Therapy in Kenya, 2013-2014.
    J Infect Dis. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. MINIOR T, Douglas M, Edgil D, Srivastava M, et al
    The Critical Role of Supply Chains in Preventing Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Settings.
    J Infect Dis. 2017 Oct 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  30. ZHUKOVA A, Cutino-Moguel T, Gascuel O, Pillay D, et al
    The Role of Phylogenetics as a Tool to Predict the Spread of Resistance.
    J Infect Dis. 2017 Oct 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  31. SINGH D, Dhummakupt A, Siems L, Persaud D, et al
    Alternative Sample Types for HIV-1 Antiretroviral Drug Resistance Testing.
    J Infect Dis. 2017 Oct 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  32. CHUN HM, Obeng-Aduasare YF, Broyles LN, Ellenberger D, et al
    Expansion of Viral Load Testing and the Potential Impact on Human Immunodeficiency Virus Drug Resistance.
    J Infect Dis. 2017 Oct 5. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2017
  33. CREANGA A, Hang NLK, Cuong VD, Nguyen HT, et al
    Highly Pathogenic Avian Influenza A(H5N1) Viruses at the Animal-Human Interface in Vietnam, 2003-2010.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  34. GUBAREVA LV, Sleeman K, Guo Z, Yang H, et al
    Drug Susceptibility Evaluation of an Influenza A(H7N9) Virus by Analyzing Recombinant Neuraminidase Proteins.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  35. ROCKWOOD N, Sirgel F, Streicher E, Warren R, et al
    Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence.
    J Infect Dis. 2017;216:632-640.
    PubMed     Text format     Abstract available


  36. MOORE T, Dembry LM, Saag MS
    Sunday in the Park with Infectious Disease: Workforce Mismatch in a Colorful Universe of Possibilities.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  37. NOGUERA-JULIAN M, Edgil D, Harrigan PR, Sandstrom P, et al
    Next-Generation Human Immunodeficiency Virus Sequencing for Patient Management and Drug Resistance Surveillance.
    J Infect Dis. 2017 Sep 15. doi: 10.1093.
    PubMed     Text format     Abstract available


  38. SHAFER RW
    Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.
    J Infect Dis. 2017 Sep 15. doi: 10.1093.
    PubMed     Text format     Abstract available


  39. GODFREY C, Bobkova M, Boucher C, Ravasi G, et al
    Regional Challenges in the Prevention of Human Immunodeficiency Virus Drug Resistance.
    J Infect Dis. 2017 Sep 14. doi: 10.1093.
    PubMed     Text format     Abstract available


  40. KISO M, Iwatsuki-Horimoto K, Yamayoshi S, Uraki R, et al
    Emergence of Oseltamivir-Resistant H7N9 Influenza Viruses in Immunosuppressed Cynomolgus Macaques.
    J Infect Dis. 2017;216:582-593.
    PubMed     Text format     Abstract available


    August 2017
  41. TUITE AR, Gift TL, Chesson HW, Hsu K, et al
    Impact of rapid susceptibility testing and antibiotic selection strategy on the emergence and spread of antibiotic resistance in gonorrhea.
    J Infect Dis. 2017 Aug 31. doi: 10.1093.
    PubMed     Text format     Abstract available


  42. OSTROSKY-ZEICHNER L, Andes D
    The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  43. LEWIS RE, Verweij PE
    Animal Models for Studying Triazole Resistance in Aspergillus fumigatus.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  44. CHOWDHARY A, Sharma C, Meis JF
    Azole-Resistant Aspergillosis: Epidemiology, Molecular Mechanisms, and Treatment.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  45. ARENDRUP MC, Patterson TF
    Multidrug-Resistant Candida: Epidemiology, Molecular Mechanisms, and Treatment.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  46. MCCARTHY MW, Kontoyiannis DP, Cornely OA, Perfect JR, et al
    Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  47. PERLIN DS, Wiederhold NP
    Culture-Independent Molecular Methods for Detection of Antifungal Resistance Mechanisms and Fungal Identification.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  48. MCCARTHY MW, Denning DW, Walsh TJ
    Future Research Priorities in Fungal Resistance.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  49. NIELSEN TB, Pantapalangkoor P, Luna BM, Bruhn KW, et al
    Monoclonal Antibody Protects Against Acinetobacter baumannii Infection by Enhancing Bacterial Clearance and Evading Sepsis.
    J Infect Dis. 2017;216:489-501.
    PubMed     Text format     Abstract available


  50. CLUTTER DS, Zhou S, Varghese V, Rhee SY, et al
    Prevalence of Drug-Resistant Minority Variants in Untreated HIV-1-Infected Individuals With and Those Without Transmitted Drug Resistance Detected by Sanger Sequencing.
    J Infect Dis. 2017;216:387-391.
    PubMed     Text format     Abstract available


    July 2017
  51. GOLDEN MR, Workowski KA, Bolan G
    Developing a Public Health Response to Mycoplasma genitalium.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  52. MARTIN DH, Manhart LE, Workowski KA
    Mycoplasma genitalium From Basic Science to Public Health: Summary of the Results From a National Institute of Allergy and Infectious Disesases Technical Consultation and Consensus Recommendations for Future Research Priorities.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  53. HORNER PJ, Martin DH
    Mycoplasma genitalium Infection in Men.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  54. BRADSHAW CS, Jensen JS, Waites KB
    New Horizons in Mycoplasma genitalium Treatment.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  55. GAYDOS CA
    Mycoplasma genitalium: Accurate Diagnosis Is Necessary for Adequate Treatment.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  56. BOUCHER HW, Ambrose PG, Chambers HF, Ebright RH, et al
    White Paper: Developing Antimicrobial Drugs for Resistant Pathogens, Narrow-Spectrum Indications, and Unmet Needs.
    J Infect Dis. 2017;216:228-236.
    PubMed     Text format     Abstract available


    June 2017
  57. GODFREY C, Thigpen MC, Crawford KW, Jean-Phillippe P, et al
    Global HIV Antiretroviral Drug Resistance: A Perspective and Report of a National Institute of Allergy and Infectious Diseases Consultation.
    J Infect Dis. 2017 Jun 17. doi: 10.1093.
    PubMed     Text format    


  58. LAVERDE D, Probst I, Romero-Saavedra F, Kropec A, et al
    Targeting Type IV Secretion System Proteins to Combat Multidrug-Resistant Gram-positive Pathogens.
    J Infect Dis. 2017;215:1836-1845.
    PubMed     Text format     Abstract available


    May 2017
  59. JAMMAL J, Zaknoon F, Kaneti G, Hershkovits AS, et al
    Sensitization of Gram-Negative Bacilli to Host Antibacterial Proteins.
    J Infect Dis. 2017;215:1599-1607.
    PubMed     Text format     Abstract available


  60. POPOVICH KJ, Snitkin ES, Hota B, Green SJ, et al
    Genomic and Epidemiological Evidence for Community Origins of Hospital-Onset Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
    J Infect Dis. 2017 May 9. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2017
  61. HAGE E, Wilkie GS, Linnenweber-Held S, Dhingra A, et al
    Characterization of human cytomegalovirus genome diversity in immunocompromised hosts by whole genomic sequencing directly from clinical specimens.
    J Infect Dis. 2017 Mar 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  62. KAKIUCHI S, Tsuji M, Nishimura H, Yoshikawa T, et al
    Association of the Emergence of Acyclovir-Resistant Herpes Simplex Virus Type 1 With Prognosis in Hematopoietic Stem Cell Transplantation Patients.
    J Infect Dis. 2017;215:865-873.
    PubMed     Text format     Abstract available


  63. MARGOT NA, Wong P, Kulkarni R, White K, et al
    Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
    J Infect Dis. 2017;215:920-927.
    PubMed     Text format     Abstract available


  64. MAVE V, Chandanwale A, Kagal A, Khadse S, et al
    High Burden of Antimicrobial Resistance and Mortality Among Adults and Children with Community-Onset Bacterial Infections in India.
    J Infect Dis. 2017 Mar 3. doi: 10.1093.
    PubMed     Text format     Abstract available


  65. OECHSLIN F, Piccardi P, Mancini S, Gabard J, et al
    Synergistic Interaction Between Phage Therapy and Antibiotics Clears Pseudomonas Aeruginosa Infection in Endocarditis and Reduces Virulence.
    J Infect Dis. 2017;215:703-712.
    PubMed     Text format     Abstract available


    February 2017
  66. RAY SM
    Preventing Methicillin-Resistant Staphylococcus aureus (MRSA) Disease in Urban US Hospitals-Now for the Hard Part: More Evidence Pointing to the Community as the Source of MRSA Acquisition.
    J Infect Dis. 2017 Feb 22. doi: 10.1093.
    PubMed     Text format    


  67. PHILLIPS AN, Stover J, Cambiano V, Nakagawa F, et al
    Impact of HIV drug resistance on HIV/AIDS associated mortality, new infections and antiretroviral therapy program costs in sub-Saharan Africa.
    J Infect Dis. 2017 Feb 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  68. GEISINGER E, Isberg RR
    Interplay Between Antibiotic Resistance and Virulence During Disease Promoted by Multidrug-Resistant Bacteria.
    J Infect Dis. 2017;215.
    PubMed     Text format     Abstract available


  69. GOMEZ-SIMMONDS A, Uhlemann AC
    Clinical Implications of Genomic Adaptation and Evolution of Carbapenem-Resistant Klebsiella pneumoniae.
    J Infect Dis. 2017;215.
    PubMed     Text format     Abstract available


  70. LOGAN LK, Weinstein RA
    The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace.
    J Infect Dis. 2017;215.
    PubMed     Text format     Abstract available


  71. MURRAY GL, Tsyganov K, Kostoulias XP, Bulach DM, et al
    Global Gene Expression Profile of Acinetobacter baumannii During Bacteremia.
    J Infect Dis. 2017;215.
    PubMed     Text format     Abstract available


  72. PARKER D
    Impact of Type I and III Interferons on Respiratory Superinfections Due to Multidrug-Resistant Pathogens.
    J Infect Dis. 2017;215.
    PubMed     Text format     Abstract available


  73. HENRY CS, Rotman E, Lathem WW, Tyo KE, et al
    Generation and Validation of the iKp1289 Metabolic Model for Klebsiella pneumoniae KPPR1.
    J Infect Dis. 2017;215.
    PubMed     Text format     Abstract available


  74. AHN D, Prince A
    Host-Pathogen Interface: Progress in Understanding the Pathogenesis of Infection Due to Multidrug-Resistant Bacteria in the Intensive Care Unit.
    J Infect Dis. 2017;215.
    PubMed     Text format     Abstract available


  75. JUAN C, Pena C, Oliver A
    Host and Pathogen Biomarkers for Severe Pseudomonas aeruginosa Infections.
    J Infect Dis. 2017;215.
    PubMed     Text format     Abstract available


    December 2016
  76. STEEGEN K, Bronze M, Papathanasopoulos MA, van Zyl G, et al
    Prevalence of Antiretroviral Drug Resistance in Patients Who Are Not Responding to Protease Inhibitor-Based Treatment: Results From the First National Survey in South Africa.
    J Infect Dis. 2016;214:1826-1830.
    PubMed     Text format     Abstract available


    November 2016
  77. GUNTHARD HF, Scherrer AU
    HIV-1 Subtype C, Tenofovir, and the Relationship With Treatment Failure and Drug Resistance.
    J Infect Dis. 2016;214:1289-1291.
    PubMed     Text format    


    September 2016
  78. YU KO, Randolph AG, Agan AA, Yip WK, et al
    Staphylococcus aureus alpha-toxin Response Distinguishes Respiratory Virus-MRSA Co-infection in Children.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  79. GRAD YH, Harris SR, Kirkcaldy RD, Green AG, et al
    Genomic epidemiology of gonococcal resistance to extended spectrum cephalosporins, macrolides, and fluoroquinolones in the US, 2000-2013.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    July 2016
  80. DOSTER RS, Kirk L, Tetz LM, Rogers LM, et al
    Staphylococcus aureus infection of human gestational membranes induces bacterial biofilm formation and host production of cytokines.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    May 2016
  81. WHITE E, Smit E, Churchill D, Collins S, et al
    No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    March 2016
  82. LANIER ER, Foster S, Brundage T, Chou S, et al
    Analysis of Cytomegalovirus DNA Polymerase Gene Mutations in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    February 2016
  83. ARAGRI M, Alteri C, Battisti A, Di Carlo D, et al
    Multiple HBV Quasispecies and Immune-Escape Mutations Are Present in HBV Surface Antigen and Reverse Transcriptase of Patients with Acute Hepatitis B.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Drug Resistance is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: